缘起进博，波士顿科学本土化“三级跳”

Core Insights - The eighth China International Import Expo (CIIE) has commenced in Shanghai, showcasing multinational medical device companies accelerating their localization efforts in China [2][3] - Boston Scientific has exhibited four unreleased products at the expo, all set to be produced at its Shanghai Lingang factory, marking a significant step in its localization journey [3][5] Localization Strategy - Boston Scientific's localization journey has progressed through three stages: from being an importer, to outsourcing production to local firms, and now establishing its own manufacturing facility in China [5][7] - The company has leveraged the Medical Device Registration Holder (MAH) system to facilitate local production, with the Polaris intravascular ultrasound system being a key milestone in this process [5][6] Recent Developments - In 2023, Boston Scientific made a strategic investment in Chinese medical device company Xianruida, enhancing its integration into the local supply chain and expanding its market reach [6][10] - The new factory in Lingang is designed to meet high standards and aims to become a leading smart factory for Boston Scientific globally, with plans for future expansion [6][7] Product Launches - By October 2024, the Lingang factory is expected to be operational, with four innovative products already in the pipeline for production, including the OptiCross/OptiCross HD catheter [9][12] - The AVVIGO+ intravascular ultrasound system, a complex machine developed with significant input from the Chinese team, is set to be one of the first products to be produced locally [12][14] Market Potential - The Chinese market is viewed as highly attractive due to its vast patient demand and the advantages of a local supply chain, which enhances efficiency and innovation [10][15] - Boston Scientific aims to better serve local markets and meet patient needs through its ongoing localization efforts, which are seen as a driving force for the company's growth in China [15]